Potential of alfacalcidol for reducing increased risk of falls and fractures

Rheumatology International

Volumn 29, Issue 10, 2009, Pages 1177-1185

  Ringe, J D ^a   Schacht, E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CORTICOSTEROID; FLUORIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PARATHYROID HORMONE; RALOXIFENE; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE; BONE DENSITY; CALCIUM ABSORPTION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FALL RISK; FALLING; FEMALE; FRACTURE; GRAFT REJECTION; HIP; HIP FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; NEUROMUSCULAR FUNCTION; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; RISK REDUCTION; SKELETAL MUSCLE; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ACCIDENTAL FALLS; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; LUMBAR VERTEBRAE; MALE; META-ANALYSIS AS TOPIC; OSTEOPOROSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 68149157443     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0835-x     Document Type: Article

References (67)

1. T Youm KJ Koval FJ Kummer JD Zuckerman 1999 Do all hip fractures result from a fall? Am J Orthop 28 190 194
2. S Kaptoge LI Benevolenskaya AK Bhalla JB Cannata S Boonen JA Falch D Felsenberg JD Finn R Nuti K Hoszowski R Lorenc T Miazgowski I Jajic G Lyritis P Masaryk 2005 Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study Bone 36 387 398 10.1016/j.bone.2004.11.012 (Pubitemid 40403837)
3. M Runge E Schacht 2005 Multifactorial pathogenesis of falls as a basis for multifactorial interventions J Musculoskelet Neuronal Interact 5 127 134
4. Ringe JD (2006) Alfacalcidol in Prevention and Treatment of all Major Forms of Osteoporosis and Renal Osteopathy. Georg Thieme Verlag, Stuttgart
5. JD Ringe E Schacht 2005 Natives vitamin D oder alfacalcidol? Prävention und Therapie von Osteoporosen Arzneimitteltherapie 23 45 53
6. E Schacht 2008 Reduction of falls and osteoporotic fractures: Plain vitamin D or D-hormone analogs? Geriatr Gerontol Int 8 Suppl 1 S16 S25
7. Ringe JD (1999) Burckhardt P (eds) VitaminD/Calcium in der Osteoporosetherapie. Georg Thieme Verlag, Stuttgart
8. E Mellanby 1919 An experimental investigation of rickets Lancet 1 407 411
9. K Huldschinsky 1919 Heilung von Rachitis durch künstliche Höhensonne Dtsch med Wschr 45 712 717
10. H DeLuca 1978 Vitamin D metabolism and function Arch Intern Med 138 836 847
11. JR Wu-Wong J Tian D Goltzman 2004 Vitamin D analogs as therapeutic agents: a clinical study update Curr Opin Investig Drugs 5 320 326
12. E Schacht 1999 Rationale for treatment of involutional osteoporosis in women and prevention and treatment of corticosteroid-induced osteoporosis with Alfacalcidol Calcif Tissue Int 65 317 327 10.1007/s002239900705 (Pubitemid 29471014)
13. HF DeLuca MT Cantorna D Vitamin 2001 Its Role and uses in immunology FASEB J 15 2579 2585 10.1096/fj.01-0433rev (Pubitemid 33131084)
14. A Inanir K Ozoran H Tutkak B Mermerci 2004 The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis J Int Med Res 32 570 582
15. SH Scharla E Schacht UG Lempert 2005 Alfacalcidol versus plain vitamin D in inflammation induced bone loss J Rheumatol 32 26 32
16. JA Kanis 1999 Vitamin D analogs: from renal bone disease to osteoporosis Kidney Int 73 Suppl S77 S81 10.1046/j.1523-1755.1999.07317.x
17. Ringe JD (ed) Calcium plus Vitamin D-Schlüsselrolle in der Osteoporose-behandlung. Georg Thieme Verlag, Stuttgart 2003
18. P Lips 2004 Which level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89-90 611 614 10.1016/j.jsbmb.2004.03.040 (Pubitemid 38844358)
19. C Kipshoven P Farahmand JD Ringe 2008 Zur Epidemiologie der vitamin D-Versorgung in Deutschland: Querschnittsuntersuchung an 1343 nicht selektierten Probanden (DeVID-Studie) Osteologie 1 A55
20. B Misra DJ McMahon SJ Silverberg JP Bikezikian 2008 New data on the impact of renal function on the relation between 25-hydroxyvitamin D and parathyroid hormone JBMR 23 suppl S10
21. E Schacht W Kneer MA Dambacher 2008 Die Wirkungen von Alfacalcidol auf den Muskel, das neuromuskulaere System, auf die Sturzgefahr und auf Frakturen J Miner Stoffwechs 15 3 132 139
22. HA Bischoff M Borchers F Gudat 2001 In situ detection of 1, 25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue Histochem J 33 19 24
23. R Boland 1986 Role of vitamin D in skeletal muscle function Endocrine Reviews 7 434 447
24. HA Bischoff-Ferrari M Borchers F Gudat U Dürmüller HB Stähelin W Dick 2004 Vitamin D receptor expression in human muscle tissue decreases with age J Bone Miner Res 19 265 269
25. HA Bischoff HB Stähelin N Urscheler 1999 Muscle strength in the elderly: its relation to vitamin D metabolites Arch Phys Med Rehabil 80 54 58
26. L Dukas E Schacht HA Bischoff 2003 Better functional mobility in community dwelling elderly is related to D-hormone and a minimal calcium intake of more than 512 mg/day Osteoporos Int 14 7 S34
27. Sorenson OH, Lund B, Saltin B (1979) Myopathy in bone loss of aging: improvement by treatment with 1-alphahydroxycholecalciferol and calcium Clin Sci (Colch) 56:157-161
28. HJJ Verhaar MM Samson PAF Jansen PL de Vreede JW Manten SA Duursma 2000 Muscle strength, functional mobility and vitamin D in older women Aging Clin Exp Res 12 455 460
29. JC Gallagher SE Fowler JR Detter SS Sherman 2001 Combination treatment with estrogen and calcitriol in prevention of age-related bone loss J Clin Endocrinol Metab 86 3618 3628
30. L Dukas HA Bischoff LS Lindpaintner E Schacht D Birkner-Binder TN Damm B Thalmann HB Stähelin 2004 Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily JAGS 52 2 230 236
31. L Dukas E Schacht Z Mazor HB Staehelin 2005 A new significant and independant risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min Osteoporosis Int 16 332 338 (Pubitemid 40379434)
32. L Dukas E Schacht Z Mazor HB Stähelin 2005 Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min Osteoporos Int 16 198 203
33. HA Bischoff-Ferrari B Dawson-Hughes WC Willett HB Staehelin MG Bazemore RY Zee JB Wong 2004 Effect of vitamin D on falls JAMA 291 16 1999 2006
34. F Richy L Dukas E Schacht 2008 Differential effects of D-hormone analogs and native vitamin D on the risk of falls: A comparative meta-analysis Calcif Tissue Int 82 102 107
35. 3 J Bon Miner Metab 10 2 50 54
36. T Tanizawa K Imura Y Ishii S Nishida Y Takano T Mashiba N Endo HE Takahashi 1999 Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study Osteoporosis Int 9 163 170
37. A Cranney G Guyatt L Griffith G Wells P Tugwell C Rosen The osteoporosis methodology group, and the osteoporosis research advisory group 2002 Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570 578 (Pubitemid 34925651)
38. E Papadimitropoulos G Wells B Shea 2002 Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women Endocrine Reviews 23 560 569 (Pubitemid 34925650)
39. F Richy O Ethgen O Bruyere J-Y Reginster 2004 Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate Osteoporos Int 15 301 310
40. C Mathieu L Adorini 2002 The coming age of 1, 25-dihydroxyvitamin D3 analogs as immunomodulatory agents Trends in Molecular Medicine 8 174 179
41. K Henderson-Briffa A Keogh PN Sambrook JA Eismann 2003 Reduction by calcitriol of immunosuppressive therapy requirements in heart transplantation Transplantation 75 2133 2134
42. TP Van Staa HGM Leufkens A Abenhaim B Zhang C Cooper 2000 Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 6 993 1000 (Pubitemid 30350061)
43. H Sasaki N Miyakoshi Y Kasukama Y Maekawa K Komo Y Shimada 2008 Effects of alfacalcidol on bone and skeletal muscle in glucocorticoid - treated rats J Bone Mineral Res 23 s427
44. JY Reginster D Kuntz W Verdickt M Wouters L Guillevin CJ Menkes K Nielsen 1999 Prophylactic use of Alfacalcidol in corticosteroid-induced osteoporosis Osteoporos Int 9 75 81
45. P Lakatos Z Nagy L Kiss C Horvath I Takacs J Foldes G Speer A Bossanyi 2000 Prevention of corticosteroid-induced osteoporosis by alfacalcidol Z Rheumatol 59 Suppl 1:I 48 52
46. JD Adachi WG Bensen F Bianchi A Cividino S Pillersdorf RJ Sebaldt P Tugwell M Gordon M Steele C Webber CH Goldsmith 1996 Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year follow up J Rheumatol 23 995 1000
47. E Shane V Addesso P Namerow D McMahon S Lo R Staron M Zucker S Pardi S Maybaum D Mancini 2004 Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation N Engl J Med 350 767 776 (Pubitemid 38209646)
48. JD Ringe A Dorst H Faber E Schacht VW Rahlfs 2004 Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis Rheumatol Int 24 63 70 (Pubitemid 38388746)
49. JD Ringe H Faber P Farahmand E Schacht 2005 Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation -induced osteoporosis J Rheumatol 32 Suppl 76 33 40
50. 3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies Osteoporos Int 15 589 602
51. JD Ringe P Farahmand E Schacht 2008 Superiority of alfacalcidol over plain vitamin D in men with osteoporosis: a prospective, observational, single center, two year trial on 214 patients J Bone Miner Res 23 S349
52. M Gambacciani A Spinetti B Cappagli M Ciaponi R Gallo LC Rovati AR Genazzani 1995 Effects of low-dose monofluorophosphate and transdermal oestradiol on postmenopausal vertebral bone loss Europ Menopause J 2 16 20
53. P Alexandersen BJ Riis C Christiansen 1999 Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study J Clin Endocriol Metab 84 3013 3020
54. JD Ringe I Setnikar 2002 Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study Rheumatol Int 22 27 32
55. WF Lems JWG Jacobs WJ Bijlsma GJM van Veen HHML Houben HCM Haanen MI Gerrits HJM van Rijn 1997 Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticoid induced osteoporosis? Ann Rheumatol Dis 56 357 363
56. JD Ringe L Rovati 2001 Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates Calcif Tissue Int 69 252 255
57. N Morabito A Gaudio A Lasco C Vergara F Tallarida G Crisafulli A Trifiletti M Cincotta MA Pizzoleo N Frisina 2003 Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis Osteoporos Int 14 500 506
58. JD Ringe A Dorst H Faber C Kipshoven LC Rovati I Setnikar 2005 Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study Rheumatol Int 25 296 300
59. JY Reginster D Felsenberg I Pavo J Stepan J Payer H Resch CC Glüer D Mühlenbacher D Quail H Schmitt T Nickelsen 2003 Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial Osteoporos Int 14 741 749
60. PD Delmas P Vergnaud ME Arlot P Pastoureau PJ Meunier MH Nilssen 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronat. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16 603 610
61. DM Black SL Greenspan KE Ensrud L Palermo JA McGowan TF Lang P Garnero ML Bouxseri JP Bilezikian CJ Rosen 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 1207 1215
62. B Frediani A Allegri S Bisogno R Marcolongo 1998 Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis two years of continuous treatment Clin Drug Invest 15 235 244 (Pubitemid 28163750)
63. Y Azuma H Takagi T Ohta H Kawaguchi 2002 Curative effect of combined treatment with alendronate and 1α-hydroxyvitamin D on bone loss by ovariectomy in aged rats Jpn J Pharmacol 89 255 266
64. JD Ringe P Farahmand E Schacht A Rozenal 2007 Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) Rheumatol Int 27 425 434
65. JD Ringe E Schacht 2007 Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol Rheumatol Int 28 103 111
66. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis Calcif Tissue Int 54 370 376
67. MW Tilyard GF Spears J Thomson S Dovey 1992 Treatment of post-menopausal osteoporosis with calcitriol or calcium New Engl J Med 326 6 357 362